Drugs / VSTs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05664126 | Aug 2023 → Dec 2028 expected | adenoviridae infectious disease, cytomegalovirus infection | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSTs | “The product is a suspension of allogenic peripheral blood VSTs enriched based on their secretion of IFN-γ after stimulation with the appropriate antigen” NCT05664126 ↗ |
| Modality | Cell therapy | “CMV- and ADV-specific T-cells” NCT05664126 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT05664126 ↗ |